What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
David F. McDermott spends much of his time researching Internal medicine, Renal cell carcinoma, Surgery, Oncology and Nivolumab.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Melanoma.
His Renal cell carcinoma research includes themes of Carcinoma and Antibody.
His Surgery research incorporates elements of Urology and Hazard ratio.
His work carried out in the field of Oncology brings together such families of science as Tolerability, Atezolizumab and Response Evaluation Criteria in Solid Tumors.
David F. McDermott combines subjects such as Clinical trial, Blockade, Everolimus, Lung cancer and Pharmacology with his study of Nivolumab.
His most cited work include:
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10003 citations)
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8133 citations)
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (3172 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and In patient.
His Internal medicine study incorporates themes from Melanoma and Surgery.
His study in Surgery is interdisciplinary in nature, drawing from both Gastroenterology, Hazard ratio, Toxicity and Urology.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Targeted therapy, Immunotherapy and Clinical trial, Phases of clinical research.
The Renal cell carcinoma study combines topics in areas such as Bevacizumab, Cancer research and Carcinoma.
The various areas that David F. McDermott examines in his Nivolumab study include Discontinuation, Antibody and Everolimus.
He most often published in these fields:
- Internal medicine (74.24%)
- Oncology (61.74%)
- Renal cell carcinoma (55.49%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (74.24%)
- Oncology (61.74%)
- Renal cell carcinoma (55.49%)
In recent papers he was focusing on the following fields of study:
David F. McDermott mostly deals with Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and In patient.
Internal medicine is a component of his Pembrolizumab, Adverse effect, Clear cell renal cell carcinoma, Clinical trial and Axitinib studies.
His studies in Pembrolizumab integrate themes in fields like Colorectal cancer, Combination therapy and Cohort.
His study looks at the relationship between Oncology and fields such as Advanced melanoma, as well as how they intersect with chemical problems.
David F. McDermott has included themes like Bevacizumab, Cancer research, Atezolizumab and Checkmate in his Renal cell carcinoma study.
His Nivolumab study deals with Ipilimumab intersecting with First line treatment, Gastroenterology and Vemurafenib.
Between 2018 and 2021, his most popular works were:
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (302 citations)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (204 citations)
- Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab (149 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
David F. McDermott mainly focuses on Internal medicine, Oncology, Renal cell carcinoma, Nivolumab and Ipilimumab.
His Oncology research includes themes of Survival rate, Adverse effect and Clinical trial, Phases of clinical research.
The study incorporates disciplines such as Pharmacokinetics, Tolerability, Blockade and Atezolizumab in addition to Renal cell carcinoma.
His Blockade study combines topics from a wide range of disciplines, such as Cancer, Cancer research and Antibody.
His work on Checkmate is typically connected to In patient as part of general Nivolumab study, connecting several disciplines of science.
His work is dedicated to discovering how Ipilimumab, Targeted therapy are connected with Vemurafenib, Dabrafenib, Cobimetinib, Sarcomatoid Features and Post hoc and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
